Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

catamaran™

NEUMEGA® (oprelvekin)

GPI CODING:

82403060002120

DESCRIPTION:

Neumega is a thrombopoietic growth factor that simulates the production of platelets. Neumega is indicated for the prevention of severe thromobocytopenia and for the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.

APPROVAL DURATION:

Approval duration: 1 year

CRITERIA FOR NEUMEGA

I. Patient is using this medication for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusion following myelosuppressive chemotherapy **AND**
II. Patient has solid tumors and lymphomas **AND**
III. Patient must have reached a platelet count of ≤ 20,000 on a prior chemotherapy cycle **OR**
IV. Patient is in a bleeding episode with a prior cycle of Neumega